The 3rd PD-1 Inhibitor, LIBTAYO, approved in Japan Sanofi’s LIBTAYO, Cemiplimab IV, was approved in December 2022 Based on results of global Ph 3 EMPOWER-Cervical 1 study, of which duration was around 6 years. This is the 3rd approval for PD-1 inhibitor in Japan following Opdivo and Keytruda. It was approved to treat patients with advanced […]

Announcement of 2023 Drug Price Revision in Japan The 2023 revision of drug prices in Japan has been announced With 600 drugs being eligible for the price maintenance premium (PMP) and 1,100 drugs eligible for the unprofitable drug reassessment. The PMP will provide an additional 0.1% to 1.0% premium for the first three years of […]